European journal of nuclear medicine and molecular imaging
-
Eur. J. Nucl. Med. Mol. Imaging · Jul 2018
Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
Dynamic 18F-FET PET/CT is a powerful tool for the diagnosis of gliomas.18F-FET PET time-activity curves (TAC) allow differentiation between histological low-grade gliomas (LGG) and high-grade gliomas (HGG). Molecular methods such as epigenetic profiling are of rising importance for glioma grading and subclassification. Here, we analysed dynamic 18F-FET PET data, and the histological and epigenetic features of 44 gliomas. ⋯ The status of dynamic 18F-FET PET as a biologically and clinically relevant imaging modality is confirmed in the context of molecular glioma diagnosis.
-
Eur. J. Nucl. Med. Mol. Imaging · Jul 2018
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ) which stratifies PRRT "responders" from "non-responders". This study clinically validates the utility of the PPQ in NETs. ⋯ The PPQ derived from circulating NET specific genes and tumor grade prior to the initiation of therapy is a highly specific predictor of the efficacy of PRRT with an accuracy of 95%.